There is increasing appreciation that mitochondria serve cellular functions beyond oxygen sensing and energy production. Accordingly, it has become important to explore noncanonical roles of mitochondria in normal and pathophysiological processes that influence airway structure and function in the context of diseases such as asthma and COPD. Mitochondria can sense upstream processes such as inflammation, infection, tobacco smoke, and environmental insults important in these diseases and in turn can respond to such stimuli through altered mitochondrial protein expression, structure, and resultant dysfunction. Conversely, mitochondrial dysfunction has downstream influences on cytosolic and mitochondrial calcium regulation, airway contractility, gene and protein housekeeping, responses to oxidative stress, proliferation, apoptosis, fibrosis, and certainly metabolism, which are all key aspects of airway disease pathophysiology. Indeed, mitochondrial dysfunction is thought to play a role even in normal processes such as aging and senescence and in conditions such as obesity, which impact airway diseases. Thus, understanding how mitochondrial structure and function play central roles in airway disease may be critical for the development of novel therapeutic avenues targeting dysfunctional mitochondria. In this case, it is likely that mitochondria of airway epithelium, smooth muscle, and fibroblasts play differential roles, consistent with their contributions to disease biology, underlining the challenge of targeting a ubiquitous cellular element of existential importance. This translational review summarizes the current state of understanding of mitochondrial processes that play a role in airway disease pathophysiology and identifying areas of unmet research need and opportunities for novel therapeutic strategies. ABBREVIATIONS: ASM = airway smooth muscle; ATP = adenosine triphosphate; CS = cigarette smoke; DAMP = damage-associated molecular pattern; Drp1 = dynamin-related protein 1; ER = endoplasmic reticulum; Fis1 = fission 1; Mfn = mitofusin; mtDNA = mitochondrial DNA; Opa1 = optic atrophy protein 1; PM = plasma membrane; ROS = reactive oxygen species
fibroblasts) and modulating effects of allergens, pollutants, cigarette smoke (CS), and inflammation all contribute to airway structural and functional changes. [1] [2] [3] [4] Within this challenging framework of disease pathogenesis, there is increasing recognition that altered mitochondrial structure and function (indeed beyond the classic role as a cell's powerhouse) occur in response to disease processes and conversely influence downstream cellular processes important in asthma [5] [6] [7] and COPD. [8] [9] [10] [11] Mitochondrial Bioenergetics and Airway Disease
Originally derived from ancient aerobic bacteria, mitochondria have their own maternally inherited DNA (mitochondrial DNA [mtDNA] ) and transcription/ translational machinery. The mitochondrial outer membrane is in contact with the cellular cytosol, whereas the highly folded inner membrane contains oxidative phosphorylation enzyme complexes and the mitochondrial matrix within (Fig 1) . Well known for meeting cellular energy demands through adenosine triphosphate (ATP) synthesis in the process of metabolizing carbohydrates and fatty acids using oxygen, mitochondria rapidly increase energy production under conditions of cellular stress (spare or bioenergetic respiratory capacity; critical for long-term cell survival). 12 One essential aspect of mitochondrial respiration is generation of reactive oxygen species (ROS), 13, 14 which serve physiological functions but are detrimental in excess (Fig 1) . Altered metabolism and increased ROS adversely affect other organelles and disrupt cellular homeostasis, requiring defense measures such as the antioxidant enzymes superoxide dismutase, peroxidases, and catalase. Mitochondrial ROS can act as signal transducers to trigger expression or release (or both) of proinflammatory cytokines, activate signaling pathways, modulate transcription factors important in redox homeostasis, proliferation/survival, response to inflammation, extracellular matrix production, and Ca 2þ regulation of epithelium and ASM. 7, [13] [14] [15] Importantly, inflammatory mediators and ROS can in turn modulate mitochondrial structure and function (see further on), creating a dysfunctional cycle to promote disease pathophysiological mechanisms.
The relevance of mitochondrial respiration to lung disease lies in increasing recognition that factors such Figure 1 -Mitochondrial structure and energetic function. Mitochondria have a cytoplasm-facing outer membrane and a highly folded inner membrane that contains the enzymes of the ETC and oxidative phosphorylation, as well as mtDNA. ROS are a normal byproduct of mitochondrial respiration. Insults such as cigarette smoke and inflammation in the context of diseases such as COPD and asthma differentially influence elements of mitochondrial respiration, overall increasing ROS production, which has downstream consequences on inflammation itself, mtDNA integrity, cytosolic Ca 2þ ([Ca 2þ ] cyt ) regulation, cell proliferation, and apoptosis (especially when severe stress induces the PTP), and in a feedback fashion, mitochondrial structure and function. b-Oxid ¼ b-oxidation; CytC ¼ cytochrome C; ETC ¼ electron transport chain; IV ¼ complex IV of the ETC; mtDNA ¼ mitochondrial DNA; PTP ¼ permeability transition pore; ROS ¼ reactive oxygen species.
chestjournal.org as inflammation in asthma and CS exposure in COPD influence bioenergetics and ROS balance (Fig 1) . In human airway cells 16, 17 and in mice chronically exposed to CS, 16 expression of oxidative phosphorylation 16 and Kreb's cycle enzymes 15, 18 is decreased, mitochondrial respiration is blunted, and respiratory reserve is suppressed. 16 Lower levels of CS blunt metabolism with a shift toward b-oxidation (Fig 1) . 19 
Dysregulation of Mitochondrial Structure in Airway Disease
It is now being recognized that beyond metabolic dysfunction, mitochondrial structure is also dynamically regulated and importantly disrupted in disease. 5, 7, 13, 28 Multiple mechanisms control the morphologic characteristics and networks of mitochondria (fusion), their disruption and fragmentation (fission), biogenesis (splitting and growth of existing mitochondria), and motility within cytoplasmic confines. Such dynamic spatiotemporal regulation is critical for mitochondrial interactions with organelles such as plasma membrane (PM), endoplasmic reticulum (ER), lysosomes, and nuclei, thus allowing mitochondria to influence a host of cellular functions such as ionic regulation (particularly Ca 2þ ), protein production, turnover, proliferation, and apoptosis. In this context, understanding the relevance of specific mitochondrial mechanisms beyond metabolism that contribute to their dysfunction in airway disease is a topic of emerging importance.
Mitochondria show cell-and context-specific heterogeneity and dynamism in morphologic features and connectivity, which are largely determined by factors that control the extent of fission vs fusion. Mitochondrial fusion is regulated by mitofusins 1 and 2 (Mfn1, Mfn2) on the outer membrane, and optic atrophy protein 1 (Opa1) on the inner membrane, 7, 28 helping to fuse the two mitochondrial membranes (Fig 2) and facilitating formation of contiguous mitochondrial chains. Fission is orchestrated by factors such as fission 1 (Fis1), mitochondrial fission factor, MiD49, and MiD51, which help form focal rings around mitochondria, recruit the cytosolic dynamin-related protein 1 (Drp1) to the mitochondrial surface and thus cleave mitochondria (Fig 2) . The normal functional relevance of mitochondrial fission and fusion is evident during the cell cycle, in which mitochondria fragment and rejoin constitutively during the quiescent G 0 phase and are extensively networked during the stable interphase. During mitosis, mitochondria are fragmented, mixed, and distributed equally among daughter cells, in which fusion then resumes.
The balance between fission and fusion can control cellular metabolism, linking mitochondrial structure to function. Interestingly, lung epithelial cells that rely on oxidative phosphorylation show more networked/fused mitochondria, 17 whereas more glycolysis-dependent cells show fragmented mitochondria. 29 chestjournal.org degrade damaged mitochondria. Other quality-control processes such as ubiquitination can affect Opa1, Drp1, and Fis1 to also influence fission/fusion balance. 7, 28, 29 Fission vs fusion pathways in different lung cell types or their contributions to specific airway diseases have been barely examined. In adult human epithelial cells 19 and ASM, 32 CS enhances fission, reflected by decreased Mfn but increased Drp1 (Fig 2) , resulting in decreased oxidative phosphorylation and a shift toward glycolysis. 16 Mitochondrial biogenesis is decreased in airways in COPD, 8, 33 although both increased fission and hyperfusion have been observed. 19, 34 In contrast, in asthma, enhanced biogenesis, 21 increased Drp1, and decreased Mfn2 35 all suggest fission (Fig 2) . (Fig 3) . The relationships between mitochondrial localization and regulation of other intracellular organelles in the context of airway disease have not been systematically examined.
Relevance of Mitochondrial Motility
Mitochondria move within the cell, 38 , activating the inflammasome, releasing mtDNA into the cytosol, and even increasing mitochondrial ROS and dysfunction. 46 ATP levels are increased in BAL fluid in COPD. 47 Less-studied DAMPs include succinate and cardiolipin, which in other cell systems elevate [Ca 2þ ] cyt and activate the inflammasome. 46 There is now increasing recognition for a role of the inflammasome in both asthma and COPD, 43, 44, [48] [49] [50] and thus emerging data suggest a role for an autocrine effect of mitochondrial DAMPs in airway disease pathophysiology.
Autophagy/Mitophagy: Emerging Concepts in the Airway
Autophagy represents a series of cellular processes for degradation or recycling of organelles and components through channeling into lysosomes, generally considered an adaptive or protective homeostatic mechanism.
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There is now considerable interest in autophagy in lung diseases, in which autophagy may be either protective for clearing cellular components damaged due to inflammation or ROS or even deleterious due to autophagic activation of fibrosis or cell proliferation. [9] [10] [11] 34 Limited data suggest a detrimental role in COPD and CS-induced epithelial cell death. 34 A selective aspect of autophagy is clearance of damaged mitochondria (mitophagy) Fig 4) , which, if left unchecked, will activate apoptotic signaling. can induce cell death, resulting in reduced numbers of functional mitochondria. The role of mitophagy in asthma has not been examined to date. In this case, mitophagyassociated proteins such as AMPK, may be particularly relevant, given AMPK's role as a sensor and regulator of cellular energy status and influences on glycolysis vs oxidative phosphorylation. 8, 9, 17, 29 Limited data suggest altered AMPK signaling in airways in COPD, 52 although the specific role of mitophagy per se is not known.
Unanswered Questions Regarding Mitochondria in Airway Diseases
Although emerging evidence highlights mitochondrial dysfunction in airway diseases, several unanswered issues relevant to asthma and COPD pathophysiology remain. Some important questions relevant to mechanism-based diagnosis and eventual therapy include:
1. Which of many metabolic, structural, localization, or functional mechanisms contribute to overall mitochondrial dysfunction in asthma vs COPD? 2. Are observed changes in these mechanisms a consequence of (or incidental to) disease and upstream processes such as inflammation or CS, or are they indeed causative? 3. By what mechanisms do insults such as inflammation (there likely being differential roles for various mediators) and oxidant stress affect relevant mitochondrial processes? 4. Are there cell-specific differences in effects of insults on mitochondrial parameters, and what are the downstream influences of mitochondrial dysfunction on physiological parameters such as mucus production, airway contractility and dilation, remodeling and fibrosis? 5. Are there age-and sex-related differences in the role of mitochondrial mechanisms in asthma or COPD? Examples include influence of mitochondrial pathways on airway development and pathophysiology of pediatric asthma or bronchopulmonary dysplasia, sex steroid influences on airway mitochondria, mitochondria-mediated senescence in aging airways, and contributions to asthma in the elderly. 6. Can mitochondrial dysfunction be detected early to allow targeting in a cell-and context-specific fashion to alleviate airway disease? Linkages between mitochondrial genes and airway disease may be particularly interesting, 53 as would mitochondria-specific ROS and DAMPs. Persistent insults may also lead to DAMPs, reduced mitochondrial biogenesis, inability to respond to cellular stresses, or a combination of these factors, which could reflect late manifestations of mitochondrial dysfunction. 7. What are the appropriate in vitro and in vivo models to explore mitochondrial dysfunction in the airway?
Therapeutic Potential of Mitochondrial Targeting
There is already interest in the idea of targeting mitochondria for therapy in airway disease 5, 28, 33 (Fig 5) .
An obvious focus has been mitochondrial ROS using antioxidants such as vitamins C and E, although such approaches have not been successful. 54 Mitochondriatargeted antioxidants such as mitoubiquinone mesylate (MitoQ) accumulate selectively within negatively charged mitochondria, suppress ROS, and protect mitochondria from oxidative damage. 5 Another mitochondria-specific antioxidant mitoTEMPO has been shown to be effective in blunting fibrosis and in mouse models of asthma. 55 Both MitoQ and
MitoTEMPO help restore mitochondrial function following CS exposure, 5 whereas MitoQ and Tiron (another mitochondria-targeted antioxidant) reverse mitochondrial dysfunction in ASM of patients with COPD and in ozone-exposure mouse models of asthma. 15 Although these initial forays into targeting oxidant stress in mitochondria are exciting, a fundamental limitation may be that mitochondrial ROS are not always detrimental and at lower levels play a protective role. Thus, knowing which cell types and under what conditions to target ROS is challenging.
Modulation of metabolism per se, while appealing, requires cell-and disease-specific approaches with a more thorough understanding of any unintended consequences of inhibiting or activating specific metabolic pathways. Modulation of mitochondrial fission/fusion balance and biogenesis are again appealing approaches if the conditions under which the need for greater fusion vs enhanced fission can be established. A potential limitation is that fission and fusion are dynamic even under normal conditions and furthermore are intricately linked to mitochondrial motility, metabolism, and downstream cellular processes. One overall problem is that mitochondrial damage may not always be evident in vivo, since damage does not always result in cell death, and conversely, some level of damage can in fact stimulate mitochondrial biogenesis. In the context of maintaining mitochondrial quality, an entirely novel approach being explored is transfer of mitochondria from bone marrow-derived mesenchymal stem cells into diseased tissues, 56 although the efficacy of such procedures remains to be established.
Conclusions
Emerging discoveries highlight normal roles of mitochondria beyond energy production, and contributions of dysfunctional mitochondrial structure and function in airway disease pathophysiology. Although we have much to understand regarding how, where, and when mitochondria play a role in modulating the many aspects of asthma or COPD processes within specific airway cell types, the concepts that mitochondria are mechanistically important, and thus should be targeted for therapy, have already been embraced and make for an exciting era in pulmonary medicine. Figure 5 -Mitochondrial dysfunction resulting from cigarette smoke and inflammation effects on various aspects of mitochondrial structure, localization, metabolism, and other mitochondrial functions contributes to asthma and COPD. Novel therapeutic approaches for airway diseases should consider mitochondria-targeted antioxidants and methods to modulate mitochondrial fission/fusion, motility, mitophagy, and other processes. See Figure 1 legend for expansion of abbreviations.
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